Stem Cell Treatment & Research Institution
|Cell Type||Pancreatic β-cell differentiated from nEPS (pluripotent stem cell)|
|Reprogramming Method||Epigenetics by STC-F002|
|Species||Homo sapiens, human|
|Origin||Mesenchymal stem cell derived from umbilical cord|
|Shipping information||Distributed frozen (volume : 1mL)|
STRI became the world’s first commercial provider of human pancreatic β-cell differentiated from human pluripotent stem cell (nEPS) without side effect and services.
This β-cell is derived from Mesenchymal stem cells (MSC) isolated from umbilical cords of healthy donor.
nEPS(newly Elicited Pluripotent Stem cell without side effects by natural products) is produced from MSC to reprogram pluripotency gene expression (OCT4, SOX2, Nanog, ETC) by treating STC-F002.
In addition, nEPS is not occurred tumor to be remarkably low expression of C-Myc gene related oncogene. Induction of nEPS do not have artificial manipulate anything and use only STC-F002 treatment, small molecules extract from natural products.Our human β-cell line will have enormous contribution to understanding the mechanism of human pancreatic β-cell development and support treatment source of diabetes.